Avacta Therapeutics
  • About
  • Our Science
  • Pipeline
  • News
  • Investors
  • Careers
  • Contact
  • About
    • About Avacta
    • Leadership
    • Scientific Resources
    • Intellectual Property
  • Our Science
    • Our Science
    • 1st Gen
    • 2nd Gen
    • 3rd Gen
    • Partners
    • Clinical trials
  • Pipeline
  • News
  • Investors
    • Investors
    • Key info
    • Corporate Governance
    • Resources
    • Share price
    • RNS News
    • Events
    • Research
  • Careers
    • Job vacancies
    • Benefits of working at Avacta
  • Contact
  • About
    • About Avacta
    • Leadership
    • Scientific Resources
    • Intellectual Property
  • Our Science
    • Our Science
    • 1st Gen
    • 2nd Gen
    • 3rd Gen
    • Partners
    • Clinical trials
  • Pipeline
  • News
  • Investors
    • Investors
    • Key info
    • Corporate Governance
    • Resources
    • Share price
    • RNS News
    • Events
    • Research
  • Careers
    • Job vacancies
    • Benefits of working at Avacta
  • Contact
Home News Diagnostics Page 2
filter by: view all | Blogs | Diagnostics | Investors | Podcasts and Videos | R&D Spotlights Series | Therapeutics

Diagnostics

29 Jun 2021

AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Detects Delta Variant

Diagnostics | Investors
21 Jun 2021

AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Distribution Agreement

Diagnostics | Investors
11 Jun 2021

Registration of Avacta’s AffiDX® SARS-CoV-2 Antigen Lateral Flow Test in EU

Diagnostics | Investors
07 Jun 2021

MHRA Confirms Registration of Avacta’s AffiDX® SARS-CoV-2 Antigen Lateral Flow Test

Diagnostics | Investors
01 Jun 2021

Update on SARS-CoV-2 Antigen Lateral Flow Test Regulatory Submissions

Diagnostics | Investors
28 May 2021

Response to speculation

Diagnostics | Investors
10 May 2021

AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Update

Diagnostics | Investors

Posts navigation

Newer posts
Avacta Therapeutics
  • Diagnostics
  • Terms of Use
  • Terms & Conditions
  • Privacy Policy
  • Intellectual Property
  • Corporate Responsibility
  • Contact Us

Avacta Group plc

Scale Space,  White City
Imperial College Campus
58 Wood Lane
London
W12 7RZ

+44 (0)20 3871 9700

Investor Enquiries

ICR Consilium
85 Gresham Street
London
EC2V 7NQ

 

Email

Twitter | Linkedin

©2025 Avacta Therapeutics. Registered company no. 06605196.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok